

PRESS RELEASE

STOCKHOLM, 23 OCTOBER 2025 10:00 CEST

Invitation to presentation of RaySearch's interim report for the third quarter of 2025

RaySearch will publish its interim report for the third quarter of 2025 on Friday, November 7, at 7.45 a.m. CET. A webcast presentation will be held at 10:00 a.m. on the same day.

Johan Löf, founder and CEO, and Nina Grönberg, CFO, will present and comment on the report. The presentation will be held in English and will be followed by a Q&A session.

Follow the webcast presentation live at: [Q3 presentation 2025](#)

Please make sure you are connected to the presentation by logging in a few minutes before it starts. You will have the opportunity to ask questions both verbally and in writing.

The presentation materials, along with the report and a recording of the presentation, will be made available on RaySearch's website.

Welcome!

For more information, please contact:

Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB

Tel: +46 (0) 708 807 173

ir@raysearchlabs.com

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

Learn more about us on:

[LinkedIn](#)

[YouTube](#)

* Subject to regulatory clearance in some markets.